MedFX

MedFX is a forex and CFD broker that operates under the official domain medbondforex.com. The company was founded on 2 December 2019 and is registered in South Africa, with a physical address at 434 Bramble Street, Waterkloof Glen, Pretoria, Gauteng, 0181. Despite its registration, MedFX does not hold any known regulatory licences from recognised financial authorities, which places it in a high-risk category for traders seeking protected and supervised trading environments.

MedFX offers three distinct ECN account types: Standard ECN, Professional ECN, and Privilege ECN. The Standard and Privilege accounts both require a minimum deposit of $500, while the Professional account demands a significantly higher minimum of $20,000. All accounts provide a maximum leverage of 1:200. The Professional ECN appears tailored to high-net-worth individuals, but the lack of transparent terms or regulatory oversight makes it difficult to assess the actual trading conditions or protections available.

The known facts do not specify which trading instruments MedFX offers, nor do they mention the trading platforms available. Typically, ECN accounts provide access to forex, indices, commodities, and sometimes CFDs on stocks or crypto. However, in the absence of official disclosures, traders cannot verify the breadth of market access or the quality of execution. The broker does not list any software partnerships, such as MetaTrader 4/5, cTrader, or proprietary platforms, leaving a significant gap in information.

MedFX has no regulatory licences on file from any major financial regulator, such as the FSCA (South Africa), FCA (UK), CySEC (Cyprus), or ASIC (Australia). This absence means that traders are not protected by investor compensation schemes or dispute resolution mechanisms. The broker's registration in South Africa does not imply active oversight; the FSCA requires a licence for forex brokerage, and MedFX does not appear on the FSCA's register of authorised financial service providers. As a result, engaging with this broker carries elevated risks, including potential issues with fund segregation, transparency, and recourse in the event of disputes.

Our analysis yields a Scam Risk Score of 48 out of 100, categorised as 'Guarded'. This score reflects the critical lack of regulatory oversight, combined with limited publicly available information about the broker's operations, management, or client reviews. While no direct evidence of fraud has been uncovered, the absence of regulation and minimal transparency justify a cautious stance. Traders are advised to conduct thorough due diligence and consider fully regulated alternatives.